Stock fact sheet · data as of
Pharming Group N.V. (PHAR): fair value, margin of safety and Wheel Score
Healthcare · Biotechnology · Netherlands · ADR · High Growth
Is PHAR undervalued?
At 9.64 (close of 16 Oct 2026), PHAR trades 50% over the GLS average fair value of 6.44, with 3 of 8 models above the price. The stock earns none of the Wheel Score's Value points at this price. That is a statement about price against trailing fundamentals, not about the company's prospects - the Wall Street View and the Growth tab on the Quote page carry the forward numbers.
There is a wide gap between Graham Number (0.3295) and DCF (12.32). When the models are this far apart the "fair value" is really a range, and the margin of safety above should be read with that range in mind.
The nightly engine files PHAR under High Growth: revenue and earnings growing fast enough that the growth-based models carry the valuation.
Nine valuation models for PHAR
Each model turns the latest filed numbers into a value per share; the GLS fair value is the simple average of the ones that produce a positive number. The last two rows are shown for reference and never enter the average. The Quote page lets you switch any model off and add your own margin of safety.
| Model | Value | vs price | What it measures |
|---|---|---|---|
| DCF | 12.32 | +28% | Present value of the projected free cash flows, discounted at the cost of capital |
| Graham Number | 0.3295 | -97% | The most a defensive investor pays for the earnings and book value per share |
| Graham Growth | 7.65 | -21% | Graham's growth formula: EPS × (8.5 + 2 × growth), adjusted for bond yields |
| Lynch | 3.34 | -65% | EPS × the earnings growth rate (PEG of 1), growth capped at 25% |
| GLS Growth | 4.77 | -51% | EPS compounded ten years at the blended growth rate, discounted back at 15% a year |
| 10 Cap | 10.53 | +9% | Owner's earnings (operating cash flow less maintenance capex) capitalised at 10% |
| Payback Time | 11.12 | +15% | Eight years of compounded free cash flow: the price at which the business pays for itself |
| DDM | - | - | Dividend discount model: next year's dividend ÷ (10% − 3% growth); needs a dividend; no value tonight |
| EPV | 1.49 | -85% | Earnings power value: current EPS capitalised at 9% with no growth |
| Zombie (liquidation) | 1.08 | -89% | Current assets less all liabilities, per share: the balance-sheet floor. Not in the average |
| Wall St target | 39.00 | +305% | Analysts' average 12-month price target. Not in the average |
Quality and financial health
Pharming Group N.V. scores 5 of 9 on the Piotroski F-score: a middling result that falls one point short of the Sunday Scan's "6 or more" rule. Some of the nine tests on profitability, leverage and efficiency are failed, so the accounts are worth a look before selling a put on the name. On durability PHAR scores 5.4/10 on the GLS Moat - a middle reading; the Scorecard on the Quote page's Financials tab shows which ten-year lines are steady and which are not.
Returns on capital are thin or negative - ROIC 0.7%, ROE 1.0%, ROA 0.6% - with debt at 0.42 times equity and a free-cash-flow yield of 4.5%.
Pharming Group N.V. pays no dividend, so the DDM model does not apply and a covered-call holder earns only the premium and any price gain.
Institutional ownership scores 1/10, insider activity 5/10 and Congressional trading 5/10 on the GLS smart-money scales.
| Piotroski F-score | 5 / 9 | ROIC | 0.7% |
|---|---|---|---|
| GLS Moat | 5.4 / 10 | ROE | 1.0% |
| Debt / equity | 0.42 | ROA | 0.6% |
| Free-cash-flow yield | 4.5% | Payout ratio | 0% |
| Institutions | 1 / 10 | Insiders · Congress | 5 · 5 / 10 |
Wheel Score 27: No options
No options are listed on Pharming Group N.V. in our nightly snapshot. The Wheel Score is therefore capped at 39 (it reads 27) and the stock is left out of every options screen; the fair value and health figures above are still useful for a plain stock position.
Volume runs at 4k shares a day on a market cap of $682M, with a beta of 0.09 - a low beta, so day-to-day moves are smaller than the market's; the Stability part of the Wheel Score gives that 7 of 20.
| Part | Points | From | |
|---|---|---|---|
| Value | 0 / 25 | -50% margin of safety | |
| Health | 11 / 20 | Piotroski 5/9 | |
| Moat | 8 / 15 | moat 5.4/10 | |
| Premium | 0 / 20 | no option data | |
| Stability | 7 / 20 | 4k shares/day, $682M cap, beta 0.09 |
The Wheel Score ranks ~7,400 US stocks for selling cash-secured puts and covered calls; it is updated nightly and is not a recommendation. The walkthrough lesson shows how the score fits into a trade, start to finish.
Upcoming events
The next earnings report is due on 5 Nov 2026 (before the open), 20 days away; a 30-45-day put sold today would expire after it, which is worth weighing against the premium.
Earnings, dividend, IPO, split and economic calendars for the whole market, filterable to your watchlists.
Similar stocks in Biotechnology
The 12 companies below are the closest to Pharming Group N.V. by market cap within the Biotechnology industry, each with its own fact sheet; the Compare page puts up to eight of them side by side.
| Stock | Close | Fair value | MoS | Wheel | Mkt cap |
|---|---|---|---|---|---|
| MDXG MiMedx Group, Inc. | 4.68 | 2.75 | -70% | 53Fair | $682M |
| CADL Candel Therapeutics, Inc. | 8.91 | 2.20 | -304% | 23Weak | $682M |
| GYRE Gyre Therapeutics, Inc. | 6.40 | - | - | 34Weak | $679M |
| OABI OmniAb, Inc. | 4.73 | - | - | 43Weak | $688M |
| ATTO Attovia Therapeutics, Inc. | 14.78 | 0.9548 | -1448% | 21No options | $675M |
| SANA Sana Biotechnology, Inc. | 2.33 | - | - | 42Weak | $698M |
| VSTM Verastem, Inc. | 7.71 | - | - | 45Weak | $698M |
| AURA Aura Biosciences, Inc. | 6.34 | 0.6743 | -840% | 30Weak | $657M |
| DSGN Design Therapeutics, Inc. | 10.48 | 0.2574 | -3971% | 25Weak | $656M |
| FDMT 4D Molecular Therapeutics, Inc. | 12.87 | - | - | 45Weak | $711M |
| ACHV Achieve Life Sciences, Inc. | 6.97 | 0.1198 | -5718% | 30Weak | $717M |
| IMMX Immix Biopharma, Inc. | 8.68 | 2.66 | -226% | 27Weak | $720M |
Screen the whole market the same way
A free GLS Equity account gets you nightly fair value and the Wheel Score on ~7,400 US stocks, a watchlist, the scanner preview and the Sunday Scan - the same eight-rule screen, emailed every week. Pro adds the full put and call scanners, unlimited watchlists with alerts and the trade journal.
Start free See the Sunday ScanQuestions about PHAR
Is PHAR undervalued right now?
No: at 9.64 the stock trades 50% above the GLS average fair value of 6.44 (data as of 16 Oct 2026), well beyond what trailing earnings, cash flow and book value support.
What is the Wheel Score of PHAR and what does it mean?
PHAR has no listed options in our nightly snapshot, so it cannot be wheeled; its Wheel Score is capped at 39 and shown as "No options".
What is the GLS fair value for PHAR?
6.44 per share as of 16 Oct 2026 - the simple average of the 8 valuation models (out of nine: DCF, Graham Number, Graham Growth, Lynch, GLS Growth, 10 Cap, Payback Time, DDM and EPV) that produced a positive value. The models run every night on the latest filings; the Quote page lets you switch any of them off and add a margin of safety of your own.
When does Pharming Group N.V. report earnings next?
The next earnings report is due on 5 Nov 2026 (before the open), 20 days from the data date of 16 Oct 2026. The Calendars page lists every upcoming report with its time of day.
Does PHAR have listed options, and how liquid are they?
No. The nightly options snapshot found no listed contracts on PHAR, so the wheel strategy cannot be run on it and the Wheel Score is capped at 39.